Objective: Evidence suggests that insulin-like growth factor-binding protein 3 (IGFBP-3) might play a role in the carcinogenesis of prostate cancer (PCa). To date, several studies have been conducted to investigate the association between IGFBP-3 -202A>C polymorphism and PCa risk in humans. However, the results remain inconclusive and inconsistent. Hence, we performed a meta-analysis of all eligible case-control studies. Methods: We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Results: 16 studies from 10 articles that included a total of 4,602 PCa cases and 4,880 controls were included in the meta-analysis. The results showed that the IGFBP-3 -A>C polymorphism was associated with a significant increase in PCa risk. The variant homozygote genotype CC of IGFBP-3 -202A>C polymorphism was associated with a significantly increased risk in homozygote comparison (OR = 1.22, 95% CI = 1.07-1.38, I2 = 36.10%) and recessive model (OR = 1.11, 95% CI = 1.00-1.22, I2 = 15.60%). In the stratified analysis, the risk remained for studies in Asian men and hospital-based studies. Conclusions: These results suggested that the IGFBP-3 -202A>C polymorphism might contribute to PCa susceptibility, especially in Asian men and hospital-based studies. Further studies are needed to confirm the relationship.

Keywords:
IGFBP-3, Polymorphism, Prostate cancer, Meta-analysis
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2.
Yoshida T, Nakayama M, Takeda K, Arai Y, Kakimoto K, Nishimura K: External validation of the cancer of the prostate risk assessment score to predict biochemical relapse after radical prostatectomy for prostate cancer in Japanese patients. Urol Int 2012;89:45-51.
3.
Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ: Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 2006;147:2112-2121.
4.
Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P: Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007;26:1811-1819.
5.
Shahjee H, Bhattacharyya N, Zappala G, Wiench M, Prakash S, Rechler MM: An N-terminal fragment of insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner. Growth Horm IGF Res 2008;18:188-197.
6.
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-566.
7.
Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB: Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000;85:4258-4265.
8.
Ehrenborg E, Larsson C, Stern I, Janson M, Powell DR, Luthman H: Contiguous localization of the genes encoding human insulin-like growth factor binding proteins 1 (IGBP1) and 3 (IGBP3) on chromosome 7. Genomics 1992;12:497-502.
9.
Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M: Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-1280.
10.
Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, Narod SA: Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1429-1437.
11.
Hoyo C, Grubber J, Demark-Wahnefried W, Marks JR, Freedland SJ, Jeffreys AS, Grambow SC, Wenham RM, Walther PJ, Schildkraut JM: Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3 -202A/C in blacks and whites. J Natl Med Assoc 2007;99:718-722.
12.
Schildkraut JM, Demark-Wahnefried W, Wenham RM, Grubber J, Jeffreys AS, Grambow SC, Marks JR, Moorman PG, Hoyo C, Ali S, Walther PJ: IGF1 (CA)19 repeat and IGFBP3 -202A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol Biomarkers Prev 2005;14:403-408.
13.
Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA: IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 2007;28:2154-2159.
14.
Park K, Kim JH, Jeon HG, Byun SS, Lee E: Influence of IGFBP3 gene polymorphisms on IGFBP3 serum levels and the risk of prostate cancer in low-risk Korean men. Urology 2010;75:1516.e1-1516.e7.
15.
Li L, Cicek MS, Casey G, Witte JS: No association between genetic polymorphisms in IGF-I and IGFBP-3 and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:497-498.
16.
Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS: Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomarkers Prev 2006;15:2461-2466.
17.
Safarinejad MR, Shafiei N, Safarinejad S: Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3. Growth Horm IGF Res 2011;21:146-154.
18.
Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, Kinoshita H, Kamoto T, Nakamura A, Ogawa O, Kato T: Insulin-like growth factor-binding protein-3 gene -202A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003;63:4407-4411.
19.
Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML: Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006;15:1993-1997.
20.
Zhang H, Xu Y, Li L, Liu R, Ma B: The interleukin-6 -174G/C polymorphism and prostate cancer risk: a systematic review and meta-analysis. Urol Int 2012;88:447-453.
21.
Wang F, Zou YF, Feng XL, Su H, Huang F: Cyp17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate 2011;71:1167-1177.
22.
Breslow NE, Day NE: Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.
23.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
24.
Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG: Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making 1994;14:108-117.
25.
Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J: A method for meta-analysis of molecular association studies. Stat Med 2005;24:1291-1306.
26.
Jernstrom H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M: Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-384.
27.
Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG: Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 2002;51:141-152.
28.
Pollak M: Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000;36:1224-1228.
29.
Liang Y, Ketchum NS, Louden C, Jimenez-Rios MA, Thompson IM, Camarena-Reynoso HR: The use of the finasteride-adjusted prostate cancer prevention trial prostate cancer risk calculator in a Mexican referral population: a validation study. Urol Int 2012;89:9-16.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.